



11th International
Respiratory Syncytial
Virus Symposium

Oct 31 - Nov 4, 2018
Omni Grove Park Inn
Asheville, NC USA



PROGRAM

DAY 1		Wednesday October 31	
1400 - 1830	Registration & Poster Setup	Vanderbilt Registration Grove Park Level 8	
1830 - 1845	Opening Address – Chair Martin Moore	Emory University Meissa Vaccines USA	
	Introduction to Keynote Speaker – Co-Chair Chris Stobart	Butler University, USA	
1845 - 1930	Keynote Address Recent Insights into the Structure, Function, and Antigenicity of the F and G Glycoproteins Jason McLellan University of Texas at Austin, USA		
1930 - 1945	In Memoriam: José Melero		
1945 - 2115	Welcome Reception	Mountain View Terrace	
End of Day 1			
DAY 2		Thursday November 1	
0630 - 0800	Breakfast		
0700 - 1000	Registration & Poster Setup		
0800 - 0930	SESSION 1 Clinical Impact and Epidemiology of RSV Moderators: Susan Gerber Centers for Disease Control and Prevention (CDC), USA Gayle Langley Centers for Disease Control and Prevention (CDC), USA		
0800 - 0830	Plenary I Strengthening Global RSV Surveillance: A Roadmap for the Future Susan Gerber Centers for Disease Control and Prevention (CDC), USA		
0830 - 0845	01 Incidence and Evaluation of the Change in Functional Status Associated with Respiratory Syncytial Virus Infection in Hospitalized Older Adults Angela Branche University of Rochester, USA		
0845 - 0900	02 Viral-bacterial interactions in infants with Respiratory Syncytial Virus Infection: Impact on clinical outcomes Asuncion Mejias The Research Institute at Nationwide Children's Hospital, USA		
0900 - 0915	03 Evaluating the diagnostic performance of various case definitions in detecting respiratory syncytial virus infections among pediatric admissions to a referral hospital, coastal Kenya Patrick Munywoki Centers for Disease Control and Prevention (CDC), Kenya		
0915 - 0930	04 Association of age at first severe RSV diseases with subsequent risk of asthma: a population-based cohort study Nusrat Homaira School of Women's and Children's Health, UNSW Medicine, Australia		
0930 - 1000	Coffee break		

1000 - 1130		SESSION 2 Recent Developments in RSV Virology
Moderators: Gaya Amarasinghe <i>Washington University, USA</i> Lindsay Broadbent <i>Queen's University Belfast, UK</i>		
1000 - 1030	Plenary 2 Immune evasion mechanisms of RSV non-structural proteins Gaya Amarasinghe Washington University, St. Louis, USA	
1030 - 1045	O5 Respiratory Syncytial Virus Binds to a Signaling Coreceptor which Induces Recruitment of its Receptor, Nucleolin, to the Cell Surface during Entry Cameron Griffiths University of Alberta, Canada	★
1045 - 1100	O6 Palladin mediates the association of RSV M protein with microfilaments in infected cells Shadi Shahriari University of Canberra, Australia	
1100 - 1115	O7 Airway epithelial and immune cell responses to RSV G protein interaction with fractalkine receptor CX3CR1 Larry Anderson Emory University, USA	
1115 - 1130	O8 Ultrastructural Studies of RSV Assembly by Cellular Cryo-Electron Microscopy Jie (Jae) Yang University of Wisconsin-Madison, USA	★
1130 - 1230	Poster Session 1	
1230 - 1330	Lunch Break <i>Blue Ridge – Grove Park Lobby level</i>	
1330 - 1500		SESSION 3 Immune Response to RSV
Moderators: Steven Varga <i>University of Iowa, USA</i> Tracy Ruckwardt <i>NIH/NIAID/VRC, USA</i>		
1330 - 1400	Plenary 3 Inflammasome Activation is Influenced by RSV Strain Differences Steven Varga University of Iowa, USA	
1400 - 1415	O9 Attenuation of human airway epithelial cell innate immune responses to respiratory syncytial virus (RSV) in newborn infants compared to older infants Helen Groves Queen's University Belfast, UK	
1415 - 1430	O10 Unraveling the respiratory syncytial virus (RSV) antibody functional repertoire in adult healthy donors Emanuele Andreano University of Siena, Italy	
1430 - 1445	O11 RSV infection in early life is associated with defective tissue resident memory T cell differentiation Mathilde Turfkruyer-Hussor Uniformed Services University of the Health Sciences, USA	
1445 - 1500	O12 Identification of novel factors associated with severe RSV disease in infants Ultan Power Queen's University Belfast, UK	
1500 - 1530	Coffee Break	
1530 - 1630		SESSION 4 Novel RSV Monoclonal Antibodies
Moderators: James Crowe <i>Vanderbilt University Medical Center, USA</i> Natalie Thornburg <i>Centers for Disease Control and Prevention (CDC), USA</i>		
1530 - 1600	Plenary 4 Neutralizing Antibody Determinants on RSV Fusion Protein James Crowe Vanderbilt University Medical Center, USA	
1600 - 1615	O13 Discovery and in vitro characterization of a potent broadly neutralizing antibody isolated from human memory B-cells Zhifeng Chen Merck & Co Inc.	

1615 - 1630	O14 A Phase 3, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of Suptavumab, for the Prevention of Medically attended RSV Infection in Preterm Infants Eric Simoes The Childrens Hospital, Colorado, USA
1630 - 1645	O15 Therapeutic potential of ALX-0171 in RSV-infected paediatric bronchial epithelium Lindsay Broadbent Queen's University, Belfast, UK
1645 - 1815	SESSION 5 Advancements in RSV Vaccines Moderators: Ursula Buchholz <i>NIH/NIAID, USA</i> Michael Teng <i>University of South Florida, USA</i>
1645 - 1715	Plenary 5 Live Attenuated Pediatric RSV Vaccines Ursula Buchholz NIH NIAID, USA
1715 - 1730	O16 WHO 1st International Standard for Antiserum to RSV Jacqueline McDonald National Institute of Biological Standards and Control (NIBSC), UK
1730 - 1745	O17 Intranasal RSV F bound to Lactococcal particles induces durable systemic immune responses in human volunteers Stephanie Ascough Imperial College London, UK
1745 - 1800	O18 Magnitude and Durability of Anti-F IgG and Palivizumab-Competitive Antibody (PCA) Responses One Year Following Immunization with RSV F Nanoparticle Vaccine Adjuvanted with Aluminum Phosphate, or a Novel Adjuvant Vivek Shinde Novavax Inc.
1800 - 1815	Janssen RSV Vaccine Program Myra Widjojoatmodjo Janssen Vaccines & Prevention B.V.
End of Day 2	
DAY 3 Friday November 2	
0630 - 0800	Breakfast
0800 - 0930	SESSION 6 RSV Protein Structure and Function Moderators: Barney Graham <i>NIH/VRC, USA</i> Annelies Leemans <i>University of Antwerp, Belgium</i>
0800 - 0830	Plenary 6 RSV F Glycoprotein Structure Determines Vaccine Immunogenicity Barney Graham NIH VRC, USA
0830 - 0845	O19 RSV F and G sequence evolution over the past three RSV seasons (2015/16-2017/2018) in the United States and Puerto Rico and implications for mAb/vaccine development Hong Jin MedImmune / AstraZeneca
0845 - 0900	O20 Characterization of Antigenic Site-Specific Competitive Antibody Responses to the Fusion Protein in RSV Infected Hematopoietic Cell Transplant Adults Xunyan Ye Baylor College of Medicine, USA
0900 - 0915	O21 New Insights into RSV Entry: ATPase Sodium/Potassium-Transporting Subunit Alpha-1 (ATP1A1) is Important for Macropinocytic Entry of RSV Matthias Lingemann National Institute of Allergy and Infectious Diseases, USA

0915 - 0930	O22 The Apical Loop of the Respiratory Syncytial Virus Fusion Protein F2 Subunit Is Critical for Fusion Activity Mark Peeples The Ohio State University, USA
0930 - 1000	Coffee Break
1000 - 1130	SESSION 7 RSV Pathogenesis and Experimental Models Moderators: Marina Boukhvalova <i>Sigmovir Biosystems, USA</i> Peter Wright <i>Geisel School of Medicine at Dartmouth, USA</i>
1000 - 1030	Plenary 7 RSV Pathogenesis, Prevention, and Animal Models Marina Boukhvalova Sigmovir Biosystems, Maryland, USA
1030 - 1045	O23 Respiratory syncytial virus (RSV) infection increases neutrophil trans-epithelial migration and adherence resulting in increased damage to ciliated airway epithelial cells Rosalind Smyth UCL GOS Institute of Child Health London, UK
1045 - 1100	O24 Genetic determinants of severe respiratory syncytial virus infections in infants Martin Wetzke Medical School Hannover, Germany
1100 - 1115	O25 MUC5B is the predominant gel-forming mucin obstructing the distal airways during RSV bronchiolitis Raymond Pickles UNC-Chapel Hill, NC, USA
1115 - 1130	O26 Streptococcus Pneumoniae Infection in Respiratory Syncytial Virus Infected Neonatal Lambs Sarhad Alnajjar Iowa State University, Oregon State University, USA
1130 - 1200	Coffee Break
1200 - 0130	SESSION 8 Anti-RSV Therapies Moderators: Janet Englund <i>Seattle Children's Hospital, USA</i> John DeVincenzo <i>University of Tennessee, USA</i>
1200 - 1230	Plenary 8 Challenges for RSV Antivirals Janet Englund Seattle Children's Hospital, University of Washington
1230 - 1245	O27 Efficacy of the non-fusion human respiratory syncytial virus (hRSV) replication inhibitor JNJ-64166037 in hRSV infected lamb model Panchan Sitticharoenchai Iowa State University, USA
1245 - 1300	O28 EDP-938, a Novel Non-Fusion Replication Inhibitor of RSV, Displays a High Barrier to Resistance In Vitro Michael Rhodin Enanta Pharmaceuticals, USA
1300 - 1315	O29 Antiviral effects, pharmacokinetics (PK) and safety of the respiratory syncytial virus (RSV) fusion protein inhibitor, JNJ-53718678 (JNJ-8678), in RSV-infected infants with bronchiolitis, in the Phase 1b Study 53718678RSV1005 Marita Stevens Janssen Infectious Diseases Bvba, Belgium
1315 - 1330	O30 Ziresovir (AK0529): Update on Clinical Development for the Treatment of Respiratory Syncytial Virus (RSV) Disease Stephen Toovey Ark Biosciences, Switzerland
1330 - 1900	Free Afternoon - Optional Activities
1900 - 2030	Robert M. Chanock Lectures <i>introduced by Peter Openshaw, Imperial College London</i>
1900 - 1945	From the Young to the Old and back again: A Journey Through the Varied World of RSV Edward Walsh University of Rochester Medical Center, USA
1945 - 2030	RSV, A Virus for All Ages Ann Falsey University of Rochester Medical Center, USA

DAY 4 Saturday November 3

0630 - 0800

Breakfast

Introduction to Keynote Speaker – Co-Chair **Natasha Halasa** Vanderbilt University, USA

0800 - 0845

Keynote Address

The Road to RSV Vaccine Impact: 'History doesn't repeat itself, but it sure does rhyme'

Katherine O'Brien

Johns Hopkins University, USA

0845 - 0855

Short Break

0855 – 1010

SESSION 9 RSV Prophylaxis and Vaccines II

Moderators: **Ruth Karron** JHU, USA

Susan Bueno Millennium Institute on Immunology and Immunotherapy, Chile

0855 - 0925

Plenary 9

The Interaction between Human Metapneumovirus and the Host Immune System

Bernadette van den Hoogen

Erasmus University, Netherlands

0925 - 0940

O31 Defining the Humoral and B Cell Response after Vaccination with a Stabilized Prefusion RSV F Subunit Vaccine (DS-Cav1)

Emily Phung

VRC; NIAID; NIH, USA

0940 - 0955

O32 Evaluation of Novel RSV Live Attenuated Vaccine in a Non-Human Primate Model

Tiffany Jenkins

Nationwide Children's Hospital Research Institute, OH, USA

0955 - 1010

Pfizer RSV Vaccine Program

Kena Swanson

Pfizer Vaccine Research

1010 - 1030

Coffee Break

1030 – 1200

SESSION 10 RSV's Global Impact and Epidemiology

Moderators: **James Nokes** KEMRI-Wellcome Trust Research Programme, Kenya

Yasmeen Agosti Pfizer Inc. USA

1030 - 1100

Plenary 10

Global perspective on the RSV problem

D. James Nokes

KEMRI-Wellcome Trust Research Programme, Kenya

1100 - 1115

O33 Global and regional disease burden estimates of respiratory syncytial virus associated with acute respiratory infections in older adults in 2015: A systematic review and meta-analysis

Ting Shi

University of Edinburgh, UK

1115 - 1130

O34 Global patterns in monthly activity of respiratory syncytial virus: a systematic review and modelling study

You Li

University of Edinburgh, UK

1130 - 1145

O35 Prospective, epidemiological study of the incidence of respiratory syncytial virus (RSV) lower respiratory tract infections (LRTIs) from birth up to 2 years of age in diverse global settings

Joanne Langley

Dalhousie University, Canada

1145 - 1200	WHO Global RSV Surveillance based on GISRS – building evidence for policy Siddhivinayak Hirve World Health Organisation
1200 - 1300	Lunch Break <i>Heritage Ballroom</i>
1300 - 1430	SESSION 11 Global Perspective of the RSV Problem Moderators: Keith Klugman <i>Bill & Melinda Gates Foundation, USA</i> Natalie Mazur <i>University Medical Centre, Utrecht</i>
1300 - 1330	Plenary 11 RSV Prevention: How to Get from The Lab to The Village Daniel Feikin World Health Organisation, Switzerland
1330 - 1335	BMGF's vision on RSV Community Mortality Studies Keith Klugman Bill & Melinda Gates Foundation, USA
1335 - 1342	RSV Gold Natalie Mazur University Medical Center Utrecht
1342 - 1349	Argentina Site Fernando Polack Fundación Infant, Buenos Aires, Argentina
1349 - 1356	RSV Burden from the CHAMPS Study Dianna Blau CDC, USA
1356 - 1403	RSV Burden from the ZPRIME Study Christopher Gill Boston University School of Public Health, USA
1403 - 1430	Executing on the vision (process, academic-community partnership, hurdles, and lessons learned) – 3 community mortality sites PANEL : INDIA - Eric Simoes <i>The Children's Hospital, Colorado, USA</i> & Ashish Satav <i>MAHAN Trust</i> ARGENTINA – Mauricio Caballero <i>Fundación INFANT, Argentina</i> ZAMBIA – Christopher Gill /Anna Williams <i>Boston University, USA</i> Lawrence Mwananyanda – Right to Care-EQUIP
1430 - 1500	Coffee Break
1500 - 1630	SESSION 12 Maternal Immunity and Maternal Vaccination Moderators: Helen Chu <i>University of Washington, USA</i> Natalie Mazur <i>University Medical Center, Utrecht</i>
1500 - 1530	Plenary 12 Maternal Immunity and Vaccination Helen Chu University of Washington, USA
1530 - 1545	O36 Transplacental Respiratory Syncytial Virus and Influenza Antibody Transfer in Alaska-Native Mother-Infant Pairs Helen Chu University of Washington, USA
1545 - 1600	O37 Efficacy of RSV Maternal Immunization Varies with the Version of the Prefusion F Antigen in Virus-like Particle Vaccine Candidates Trudy Morrison University of Massachusetts Medical School, USA
1600 - 1615	O38 Progress Toward a Vaccine for Maternal Immunization to Prevent Respiratory Syncytial Virus Lower Respiratory Tract Illness (RSV LRTI) in Infants Louis Fries Novavax, Inc.
1615 - 1630	O39 Advancing Maternal Immunization and the RSV MI Roadmap Deborah Higgins PATH, USA

End of Day 4

1800 - 2200

Ticketed SOCIAL EVENT – Conference Dinner at the Biltmore

Shuttles will depart at 6pm from the Vanderbilt Wing Lobby, Grove Park Level 7

DAY 5

Sunday November 4 - Departures



Young Investigator Best Abstract Award